全文获取类型
收费全文 | 2345篇 |
免费 | 168篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 50篇 |
妇产科学 | 61篇 |
基础医学 | 370篇 |
口腔科学 | 31篇 |
临床医学 | 149篇 |
内科学 | 360篇 |
皮肤病学 | 432篇 |
神经病学 | 279篇 |
特种医学 | 37篇 |
外科学 | 183篇 |
综合类 | 20篇 |
一般理论 | 1篇 |
预防医学 | 226篇 |
眼科学 | 39篇 |
药学 | 131篇 |
中国医学 | 20篇 |
肿瘤学 | 130篇 |
出版年
2024年 | 2篇 |
2023年 | 12篇 |
2022年 | 43篇 |
2021年 | 67篇 |
2020年 | 46篇 |
2019年 | 78篇 |
2018年 | 76篇 |
2017年 | 77篇 |
2016年 | 66篇 |
2015年 | 97篇 |
2014年 | 117篇 |
2013年 | 127篇 |
2012年 | 181篇 |
2011年 | 183篇 |
2010年 | 94篇 |
2009年 | 101篇 |
2008年 | 158篇 |
2007年 | 148篇 |
2006年 | 145篇 |
2005年 | 142篇 |
2004年 | 114篇 |
2003年 | 88篇 |
2002年 | 83篇 |
2001年 | 24篇 |
2000年 | 28篇 |
1999年 | 24篇 |
1998年 | 28篇 |
1997年 | 19篇 |
1996年 | 19篇 |
1995年 | 13篇 |
1994年 | 8篇 |
1993年 | 9篇 |
1992年 | 14篇 |
1991年 | 19篇 |
1990年 | 14篇 |
1989年 | 13篇 |
1988年 | 14篇 |
1987年 | 6篇 |
1986年 | 5篇 |
1985年 | 6篇 |
1984年 | 3篇 |
1983年 | 2篇 |
1982年 | 2篇 |
1981年 | 3篇 |
1979年 | 3篇 |
1978年 | 2篇 |
1973年 | 2篇 |
1968年 | 1篇 |
1933年 | 1篇 |
1905年 | 1篇 |
排序方式: 共有2532条查询结果,搜索用时 15 毫秒
1.
C. J. M. Antens M. Oldenwening A. Wolse U. Gehring H. A. Smit R. C. Aalberse M. Kerkhof J. Gerritsen J. C. de Jongste B. Brunekreef 《Clinical and experimental allergy》2006,36(12):1525-1531
BACKGROUND: Studies of the association between indoor allergen exposure and the development of allergic diseases have often measured allergen exposure at one point in time. OBJECTIVE: We investigated the variability of house dust mite (Der p 1, Der f 1) and cat (Fel d 1) allergen in Dutch homes over a period of 8 years. METHODS: Data were obtained in the Dutch PIAMA birth cohort study. Dust from the child's mattress, the parents' mattress and the living room floor was collected at four points in time, when the child was 3 months, 4, 6 and 8 years old. Dust samples were analysed for Der p 1, Der f 1 and Fel d 1 by sandwich enzyme immuno assay. RESULTS: Mite allergen concentrations for the child's mattress, the parents' mattress and the living room floor were moderately correlated between time-points. Agreement was better for cat allergen. For Der p 1 and Der f 1 on the child's mattress, the within-home variance was close to or smaller than the between-home variance in most cases. For Fel d 1, the within-home variance was almost always smaller than the between-home variance. Results were similar for allergen levels expressed per gram of dust and allergen levels expressed per square metre of the sampled surface. Variance ratios were smaller when samples were taken at shorter time intervals than at longer time intervals. CONCLUSION: Over a period of 4 years, mite and cat allergens measured in house dust are sufficiently stable to use single measurements with confidence in epidemiological studies. The within-home variance was larger when samples were taken 8 years apart so that over such long periods, repetition of sampling is recommended. 相似文献
2.
Marjan Boerma Gregory R Burton Junru Wang Louis M Fink Robert E McGehee Martin Hauer-Jensen 《Blood coagulation & fibrinolysis》2006,17(3):173-180
Immortalized cell lines offer significant logistical advantages over primary cells when used for in-vitro studies. Immortalized cells may, however, exhibit important differences relative to their primary cell counterparts. In this study, microarrays were used to make a genome-wide comparison between primary human umbilical vein endothelial cells (HUVECs) and EA.hy926, an immortalized HUVEC cell line, in their baseline properties and in their response to inhibition of the mevalonate pathway with an inhibitor of hydroxy methylglutaryl-coenzyme A reductase (statin). HUVECs and EA.hy926 were incubated with control medium, atorvastatin, mevalonate, or a combination of atorvastatin and mevalonate for 24 h. Gene expression profiles were obtained in duplicates using Affymetrix Human Genome U133A 2.0 arrays (Santa Clara, California, USA). Probe-sets were selected according to the following criteria: a twofold or greater increase/decrease in atorvastatin-treated cells compared with untreated cells; a twofold or greater reversal of the effect of atorvastatin by combined treatment with atorvastatin and mevalonate; no significant change in gene expression in cells treated with mevalonate alone compared with untreated cells. Most genes that were expressed by untreated HUVECs, were also expressed by untreated EA.hy926 cells. EA.hy926 cells, however, constitutively expressed a large number of additional genes, many of which were related to cell cycle control and apoptosis. Atorvastatin induced differential expression (> or = twofold) of 103 genes in HUVECs (10 up, 93 down) and 466 genes in EA.hy926 cells (198 up, 268 down). Applying the above selection criteria, thrombomodulin and tissue plasminogen activator were up-regulated in both cell types, whereas, connective tissue growth factor, thrombospondin-1, and cysteine-rich angiogenic inducer 61 were down-regulated. In conclusion, EA.hy926 cells retain most of the characteristics of endothelial cells under baseline conditions as well as after treatment with atorvastatin. It is necessary, however, to carefully select and validate changes in genes that are the focus of studies when using EA.hy926 cells. While this cell line is highly useful in studies on some genes, including genes encoding molecules involved in regulating thrombohemorrhagic homeostasis, they appear to be less suited for studies focused on other genes, particularly those involved in the regulation of cell proliferation and apoptosis. 相似文献
3.
Raph Hamers Sander Bontemps Marjan van den Akker Ruy Souza Júlio Penaforte Niels Chavannes 《Primary care respiratory journal》2006,15(5):299-306
AIMS: The developing world is particularly at risk of an increasing health burden due to an increased prevalence of Chronic Obstructive Pulmonary Disease (COPD) secondary to increasing tobacco consumption. However, research is scarce. The objectives of this study were to assess the current competence for diagnosing COPD in primary care in a resource-limited setting in Brazil, and to develop a local patient profile for case-finding. METHODS: 34 general practitioners (GPs) in five areas of northern Brazil recruited adult patients with principal complaints of cough and/or shortness of breath who then had spirometry (n = 142). RESULTS: For the dichotomous variable 'COPD' the degree of agreement between GP diagnosis (n = 64, 18.3%) and spirometric outcome (n = 36, 25.4%) was poor, with Kappa = 0.055 (SE 0.087) and DOR = 1.35. False-positive and false-negative diagnosis proportions were 19.8% and 75%, respectively. Independent risk factors were 'smoking history of more than five pack years' and 'presence of both dyspnoea and cough'. It requires the testing of 2.2 smokers with more than five pack years to detect one patient at risk. CONCLUSIONS: COPD is a common yet underdiagnosed disease in Brazilian primary care. Spirometry improves diagnostic competence and case-finding substantially. If applied in a pre-selected high-risk population, we believe spirometry can be a cost-effective diagnostic tool for case-finding in the resource-limited setting. This study provides important baseline information for effective guideline implementation. 相似文献
4.
5.
6.
7.
Ute Bültmann Renée-Louise Franche Sheilah Hogg-Johnson Pierre Côté Hyunmi Lee Colette Severin Marjan Vidmar Nancy Carnide 《Quality of life research》2007,16(7):1167-1178
BACKGROUND: The purpose of this study was to describe the health status and work limitations in injured workers with musculoskeletal disorders at 1 month post-injury, stratified by return-to-work status, and to document their return-to-work trajectories 6 months post-injury. METHODS: A sample of 632 workers with a back or upper extremity musculoskeletal disorder, who filed a Workplace Safety and Insurance Board lost-time claim injury, participated in this prospective study. Participants were assessed at baseline (1 month post-injury) and at 6 months follow-up. RESULTS: One month post-injury, poor physical health, high levels of depressive symptoms and high work limitations are prevalent in workers, including in those with a sustained first return to work. Workers with a sustained first return to work report a better health status and fewer work limitations than those who experienced a recurrence of work absence or who never returned to work. Six months post-injury, the rate of recurrence of work absence in the trajectories of injured workers who have made at least one return to work attempt is high (38%), including the rate for workers with an initial sustained first return to work (27%). CONCLUSIONS: There are return-to-work status specific health outcomes in injured workers. A sustained first return to work is not equivalent to a complete recovery from musculoskeletal disorders. 相似文献
8.
The concept of a first night effect on sleep patterns, specifically in relation to age is a controversial topic in the literature. Our data are obtained during two consecutive 24-h ambulatory home sleep-wake recording in 10 elderly persons with a mean age of 85.5 years. Polysomnographic recordings indicated that a first night effect is present in old age, even using home recording, and that several types of insomnia can be differentiated, stressing that sleep cycle parameters should be taken into account. It is suggested that the first night effect is a 'miniature' replication of a psychophysiological insomnia. 相似文献
9.
PCM van de Kerkhof 《Journal of the European Academy of Dermatology and Venereology》2006,20(6):639-650
Psoriasis is a chronic, incurable disease that frequently requires long-term treatment. Although many patients benefit from effective traditional systemic therapies, namely methotrexate, cyclosporin, retinoids and fumaric acid esters, and some patients achieve long-term disease control, unrestricted long-term administration is not recommended due to the potential for cumulative toxicity. In order to diminish the risk of toxicity, physicians have adopted various treatment approaches (e.g. rotational, sequential, intermittent, and combination). However, these approaches may not provide continuous disease control or a stable treatment regimen. The recent advent of targeted biological therapeutics such as etanercept, infliximab, adalimumab, alefacept and efalizumab may offer physicians and their patients treatment options with improved safety profiles that may permit continuous disease control. 相似文献
10.